Results showed that GBM (grade IV) had higher levels of non-phosphorylated CaMK2A vs. the lower grades, suggesting that a regulated “phosphorylation inhibition of CaMK2A” was essential for glioblastoma progression to aggressive and malignant form (Figure 2). Here, CAMK2A is linked to glioblastoma.